• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Enhatch Partners with Holo-Light to Deliver New Extended Reality Streaming Platform

    Study Confirms Safety, Accuracy of Vectorious' V-LAP In-Heart Sensor

    Norman Noble Achieves ISO 13485:2016 Certification

    Indian SMEs Gaining Access to Russian Medtech Market Amid Ukraine Conflict

    Quell Wearable Neuromodulation Device Wins De Novo Authorization
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Xact Wire EDM Corp.

    Concise Engineering

    BMP Medical

    Fusion Biotec Inc.

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    ‘Right to Repair’: Separating Fact from Fiction

    Taking a Holistic Approach to Decentralized Clinical Trials (DCTs)

    Investment in Health Startups Drops

    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Xact Wire EDM Corp.

    Concise Engineering

    BMP Medical

    Fusion Biotec Inc.

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Guidance on Skin Irritation With a Push to Achieve the 3 Rs

    The publication of ISO 10993-23:2021 marks a paradigm shift in prioritizing in-vitro testing alternatives within the medical device biocompatibility space.

    Guidance on Skin Irritation With a Push to Achieve the 3 Rs
    Nick Hibbard, In-Vitro Scientific Research Fellow at WuXi AppTec Medical Device Testing07.22.21
    The publication of ISO 10993-23:2021 in January 2021 marks a paradigm shift in prioritizing in-vitro testing alternatives within the medical device biocompatibility space. Drafting for ISO 10993-23 has been in progress for years and its debut has been anticipated for many reasons—chief among them is the potential to reduce in-vivo irritation test methods.

    In 2003, a validation study from the European Centre for the Validation of Alternative Methods (ECVAM) laid the groundwork for ISO 10993-23. The Centre focuses on safety assessments for chemical, agricultural, and cosmetic products with the goal of reducing, refining, and replacing in vivo testing wherever possible. The skin irritation assay ECVAM initially used as part of a cosmetic directive evolved to become ISO 10993-23 within the medical device space. And, publishing the new standard means ISO officially recognizes in-vitro irritation testing as an approved method for understanding, predicting, and classifying the potential for skin irritation risk in medical devices.

    But that does not mean regulatory bodies worldwide have completely followed suit. ISO 10993-23 is relatively new, and regulators are still interpreting it according to their individual mandates. It’s critical to stay informed about what guidance comes from which regulatory body and ensure medical device submissions are aligned accordingly. Keeping a pulse on the regulatory landscape is important, as evolving guidance could impact test programs.

    Unpacking ISO 10993-23:2021
    The standard represents a split from ISO 10993-10—an assessment of irritation and sensitization. As a part of the ISO 10993 family of standards that assesses biological risks in medical devices, ISO 10993-23 includes new language that will require in-vitro testing for skin irritation, but only for specific contact points.

    The standard’s approved in-vitro methods are limited to contact points located on epidermal tissue. At the time of publication, ISO 10993-10 still contained language relating to irritation and sensitization. But as ISO 10993-23 becomes a more popular standard for testing irritation, ISO 10993-10 will eventually focus exclusively on sensitization. Until that happens, however, two standards exist to evaluate the irritant potential in medical devices, with ISO 10993-23 being the preferred method.

    ISO created a step-by-step directive to maximize thoroughness and outline how to use the two standards in concert. The five steps include:

    • Performing a chemical characterization of medical device materials, residue, and additives.
    • Conducting a literature review to evaluate a device’s chemical and physical properties, as well as the irritation potential of any extracts or constituents.
    • Conducting in-vitro testing using reconstituted human epidermis (RhE).
    • Conducting in vivo testing when device materials cannot be characterized and risk assessments cannot be undertaken.
    • Performing non-invasive clinical studies only after irritancy potential is established using one of the aforementioned methods.

    The Business Case for In-Vitro Skin Irritation Assays
    One of the most valuable characteristics of ISO 10993-23 is the robustness of the in-vitro assay. Part of the development included a large round-robin study that tested two types of RhE. The study demonstrated that in-vitro models can detect irritant chemicals extracted from PVC and silicone—two materials commonly used in medical device production. The study was conducted across different geographies and laboratory environments and found the assay to be equally sensitive in detecting low concentrations of some potent irritant compounds. Previous methods for this type of detection were limited to human patch testing and other in vivo methods.

    Because the assay is robust and repeatable, it can also be a valuable safeguard. Cytotoxicity testing helps assess the potential for a test article to inhibit cell growth or cause cell death. Likewise, pyrogenicity testing determines the presence of foreign substances that may trigger a fever response. Used together, an in-vitro skin irritation, pyrogenicity, and cytotoxicity panel of tests may provide a formidable battery of biocompatibility testing that could enable researchers to proactively remove problematic test articles early in their development. Depending on manufacturers’ regulatory strategy and the market they would like to enter, this biocompatibility trifecta could also serve as a proactive measure before moving into any in-vivo testing the local regulatory agency may require.

    Manufacturers hoping to leverage the in-vitro skin irritation test as a screening method must understand their product’s origins and components, down to the coatings, packaging, materials, and products or methods used for sterilization. A coating, for example, might not be central to a device’s design and functionality, but it can still be a source of irritation that gets flagged during testing. Put simply, any combination of these variables could create an irritation that has the potential to undermine a regulatory application and require revisiting a completed design.

    Emerging In-Vitro Modalities
    As the use of in-vitro modalities increases, in-vitro skin irritation testing could conceivably become the preferred approach. Regulatory bodies will take some time to interpret the test method and issue guidance and, as such, there will still be a time and place for in vivo methods for the foreseeable future. But the primary appeal of in-vitro modalities will always be their adherence to the scientific tenets of the three Rs: replacement, reduction, and refinement.

    The publication of ISO 10993-23 has bolstered the case for using in-vitro assays to assess skin irritation whenever possible. In fact, regulatory bodies in parts of Asia and the European Union have already deemed in-vitro testing as the preferred method for assessing skin irritation. But companies should always consider the market in which they plan to launch their products and ensure the regulatory guidance in those locations matches their testing processes. In the past, medical devices that tested negative or inconclusive for irritation would still require an in vivo evaluation, but under the ISO 10993-23 revisions, regulators can now accept both positive and negative results, should they choose to do so.

    The bottom line is, ISO 10993-23 is still in its infancy and applying it can be confusing. This might make it challenging for manufacturers to fully understand the regulatory guidance that applies to the particular products in each region. Manufacturers that collaborate with testing partners can gain a better understanding of how regulatory bodies interpret ISO standards. Engaging the right testing partner can also build confidence in facing an evolving regulatory landscape and it can help manufacturers build the best and safest device possible.

    Prioritizing Safety
    The ISO 10993-23 guidance is just the beginning. It is unlikely that in biological evaluations overall, in-vitro methods will totally replace in vivo methods, but the journey has begun. In vivo skin irritation testing is a robust and repeatable complement to the ISO 10993 guidance that can add efficiency to manufacturing processes and preserve valuable resources along the way. The standard offers a trustworthy alternative to in vivo testing that can, in some cases, help reduce, refine, and replace the use of test articles in skin irritation assessments.

    Managing risk and prioritizing patient safety will always be the central goals in evaluating medical device biocompatibility. The ISO 10993 standard is continuously evolving to support this endeavor. Collaborating with a qualified laboratory testing partner with expert knowledge of the shifts and changes within the guidance documents will help ensure successful submissions. 


    Nick Hibbard earned a bachelor of science degree from Bowling Green State University and a master of science degree from the University of Liverpool, where he wrote his dissertation, “Accuracy and precision of liver based in-vitro models relating to pre-clinical drug screening.’’ Hibbard has more than 10 years of direct experience within the field of in-vitro sciences, ranging from standard guideline driven assays to complex novel assay development. Currently he is the in-vitro Scientific Research Fellow at WuXi AppTec Medical Device Testing in St. Paul, Minn. Within this position he is responsible for troubleshooting assay deviations, novel assay development, and validating current approved assays for service.
    Related Searches
    • Testing
    Related Knowledge Center
    • Testing
    Loading, Please Wait..

    Trending
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • FDA OKs J&J Vision's AcuVue Oasys Max 1-Day Contact Lenses
    • How To Overcome The Top 6 Medical Device Manufacturing Challenges
    • Cepheid, BioGX Partner To Create GeneXpert Monkeypox Test
    • Intermountain Healthcare & Siemens Healthineers Open 3 Tellica Outpatient Imaging Centers
    Breaking News
    • Varian Receives IDE Exemption from FDA to Advance Flash Clinical Research Program
    • Enhatch Partners with Holo-Light to Deliver New Extended Reality Streaming Platform
    • Study Confirms Safety, Accuracy of Vectorious' V-LAP In-Heart Sensor
    • Norman Noble Achieves ISO 13485:2016 Certification
    • Indian SMEs Gaining Access to Russian Medtech Market Amid Ukraine Conflict
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kensing Acquires Vitae Naturals
    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise
    Shiitake Mushroom Extract Appears Helpful in HPV Infections
    Coatings World

    Latest Breaking News From Coatings World

    PPG to Increase U.S. Aerospace Products Manufacturing Output to Meet Rising Demand
    Solvay to Discontinue Use of Fluorosurfactants for Production of Fluoropolymers
    AkzoNobel Names New CEO
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Enhatch Partners with Holo-Light to Deliver New Extended Reality Streaming Platform
    Study Confirms Safety, Accuracy of Vectorious' V-LAP In-Heart Sensor
    Norman Noble Achieves ISO 13485:2016 Certification
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Shimadzu Scientific Instruments Extends HQ Campus
    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
    Batavia Enters Commercial Manufacturing Business
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Naples Soap Company to Open New Store in Venice, Florida
    Nectar Recruits 8-Year-Old YouTube Star to Launch Her Own Bath & Body Line
    L'Oreal Exec Joins Function of Beauty
    Happi

    Latest Breaking News From Happi

    Rhode Island’s Department of Health, Raw Elements and Partners Expand Touch-Free Mineral Sunscreen
    Julee Wilson Named Executive Director of BeautyUnited
    Arey Launches Unisex Leave-In Conditioner
    Ink World

    Latest Breaking News From Ink World

    Amcor Lift-Off Initiative Shortlists Start-ups for Seed Funding
    Barentz Highlights Lincoln MFG’s New ISO 9001:2015 Certification
    Ingevity Appoints Christine Stunyo as Chief Human Resources Officer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood introduces Sitexco Label L10 anilox cleaning system
    Germark makes double press investment in Bobst
    UPM Raflatac to enhance service capabilities at Mills River factory
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Rockline's Springdale Campus Achieves 15 Million Safe Work Hours
    Emmanuelle Picard to Join Ahlstrom-Munksjö's Executive Management Team
    Alkegen Completes Luyang Acquisition
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Researchers Develop Microfluidic Sensors to Improve Implant Survival Rates
    Lawrence Yellin Appointed as Fuse Medical CFO
    Researchers Discover Novel Patching Material for Bone Defects
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Avery Dennison Highlights New Approach to Apparel with ADX Lab
    trinamiX Face Authentication Protects Users from Fraud Attacks During Mobile Payments
    Hugo Boss Partners with Nedap for Global RFID Roll-out

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login